# **Supplementary Information**

# Identification of a New Cell Population Constitutively Circulating in Healthy Conditions and Endowed with a Homing Ability Toward Injured Sites.

Claudia Lo Sicco<sup>1,2,3</sup>, Roberta Tasso<sup>1,2,3\*</sup>, Daniele Reverberi<sup>2</sup>, Michele Cilli<sup>2</sup>, Ulrich Pfeffer<sup>2</sup> & Ranieri Cancedda<sup>1,2</sup>

<sup>1</sup>Department of Experimental Medicine (DIMES), University of Genova, Genova, 16132, Italy

<sup>2</sup>A.O.U. San Martino-IST, National Cancer Research Institute, Genova, 16132, Italy

<sup>3</sup> These authors contributed equally to this study.

\* Correspondence: robertatasso@gmail.com

\* Work telephone number: +39-010-5558319



Supplementary Fig. S1. Back-gating of Lin<sup>neg</sup>CD45<sup>neg</sup>Vybr<sup>pos</sup> (CH) cells. (a) Representative
flow cytometric analysis of CH cells back-gated in the dot plot of side scatter (SSC-A) versus Sytox
AADvanced dye. (b) Doublet discrimination. CH cells are shown in fuchsia.



Supplementary Fig. S2. Identification of RFP<sup>pos</sup> CH cells. (a-c) Representative flow cytometry

strategy used to identify Lin<sup>neg</sup>CD45<sup>neg</sup>Vybr<sup>pos</sup> (CH) cells in the peripheral blood of C57Bl/6 transgenic for the ubiquitous RFP expression (Lin<sup>neg</sup>CD45<sup>neg</sup>Vybr<sup>pos</sup>RFP<sup>pos</sup>). DG, dimensional gate; LEU, leukocytes. (**d**, **e**) Re-analysis of sorted RFP<sup>pos</sup> CH cells based on intrinsic fluorescence (Vybrant and RFP)and physical parameters. (**f-i**) Representative flow cytometry analysis of RFP<sup>pos</sup> cells present in the peripheral blood of fractured PBS-injected mice (**f**,**g**) and fractured cell-injected mice (**h**,**i**) 24 days post-fracture induction.



**Supplementary Fig. S3. RFP**<sup>pos</sup> **CH cells differentiate into tissue-specific cells.** (**a**-**c**) Serial sections of hard callus formed after 24 days in fractured and cell injected mice. (**a**) Representative immunohistochemical analysis conducted using a specific anti-RFP antibody; (**b**) Representative control with pre-immune serum. (**d**-**f**) Serial sections of the knee region of fractured and cell injected mice. (**d**) Representative immunohistochemical analysis conducted using a specific anti-Osteocalcin antibody; (**c**) Negative control with pre-immune serum. (**d**-**f**) Serial sections of the knee region of fractured and cell injected mice. (**d**) Representative immunohistochemical analysis conducted using a specific anti-RFP antibody; (**e**) Representative immunohistochemical analysis conducted using a specific anti-RFP antibody; (**e**) Representative immunohistochemical analysis conducted using a specific anti-

type II Collagen antibody; (**f**) Negative control with pre-immune serum. (**g-i**) Serial sections of muscle tissue surrounding the callus formed after 24 days in fractured and cell injected mice. (**g**) Representative immunohistochemical analysis conducted using a specific anti-RFP antibody; (**h**) Representative immunohistochemical analysis conducted using a specific anti-Dystrophin antibody; (**i**) Negative control with pre-immune serum. Each panel is the merged result of 6 serial microscope images. Magnification 100X; scale bar, 50 μm.



**Supplementary Fig. S4. Presence of CH cells in the damaged tissues.** (a) Quantification of RFP<sup>pos</sup> and RFP<sup>neg</sup> cells engrafted in the hard callus (upper panels) and in the knee region (bottom panels). The yellow lines indicate two representative regions of interest (ROI). (b) Representative double immunohistochemical analysis conducted using a specific anti-dystrophin antibody revealed in light blue and a specific anti-RFP antibody revealed in brown. Muscle tissue adjacent to the hard callus (upper panel) and out of the hard callus region (bottom panel) were analyzed. Magnification 40X; scale bar, 50 mm.